Navigation Links
Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
Date:8/13/2013

LA JOLLA, Calif., Aug. 13, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the quarter ended June 30, 2013 and provided a summary of recent corporate highlights. 

"The second quarter was a period of significant progress for Regulus.  We continued to execute on our 'Road to the Clinic' strategy and are preparing for clinical development of RG-101, a GalNAc-conjugated anti-miR which targets miR-122 for HCV. We also made great progress across the pipeline, advancing additional proprietary and partnered programs and identifying attractive new opportunities to broaden our microRNA platform," said Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus.  "On the business front, we had a very productive quarter and recent period. We are pleased to have entered into an exclusive option agreement with Sanofi to negotiate the terms of a potential new relationship.  Additionally, we strengthened our balance sheet with a successful public offering which will enable us to accelerate our 'Road to the Clinic' goals, expand our microRNA therapeutic pipeline and increase our cash runway to fund our operations into 2017."

"These recent accomplishments have positioned us for an exciting period focused on scientific execution," said Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus.  "We look forward to entering the clinic with RG-101, nominating a second candidate for clinical development by the end of the year, and continuing to build a meaningful clinical pipeline based on microRNAs."Recent Corporate Highlights

  • Secured Rights to Proprietary Process for Manufacturing GalNAc Conjugates from Alnylam.  Regulus entered into an
    '/>"/>

  • SOURCE Regulus Therapeutics Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
    2. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
    3. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
    4. Regulus Provides Update on Road to the Clinic Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
    5. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
    6. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
    7. Regulus to Present at Future Leaders in the Biotech Industry Conference
    8. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
    9. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
    10. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
    11. Regulus to Present at Two Upcoming Investor Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... DUBLIN , Aug. 29, 2014 Research ... CNS Disorders Drug Pipeline Insight 2014" report to their ... market in US is one of the largest segments of ... an alarming rate, while the available therapies were unable to ... growth in the market for CNS disorder, especially over the ...
    (Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... District Court for the District of New ... the company,s case against Sandoz, Inc. regarding United Therapeutics, ... Sheridan ruled that U.S. Patent No. 6,765,117 is ... Sandoz from marketing its generic product until the expiration ...
    (Date:8/29/2014)... Pa. , Aug. 29, 2014  Unilife Corporation ... UNS) announced today that it intends to release its ... year ended June 30, 2014 after market trading ends ... has scheduled a conference call for 4:30 p.m. U.S. ... 2014 at 6:30 a.m. AEST), to review the Company,s financial ...
    Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
    ... 2011 ChromaDex® Corp. (OTCBB: CDXC) today announced ... ChromaDex® the exclusive rights to a joint patent ... the method of inducing UDP-glucuronosyltransferase (UGT) activity using ... found in blueberries and demonstrated to have multiple ...
    ... (Nasdaq: NKTR ) today announced that dosing ... multiple ascending doses of NKTR-181, the company,s novel opioid ... once- or twice-daily oral tablet for the treatment of ... liability and serious central nervous system (CNS) side effects ...
    Cached Medicine Technology:ChromaDex®'s Novel Ingredient pTeroPure® to be Studied as Potential Treatment for Fighting Skin Cancers 2ChromaDex®'s Novel Ingredient pTeroPure® to be Studied as Potential Treatment for Fighting Skin Cancers 3Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 2Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 3Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 4Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 5Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 6
    (Date:8/30/2014)... a plant-based medication commonly used to treat gout, ... in reducing potential complications from this type of ... gastrointestinal adverse effects, according to a study published ... released early online to coincide with its presentation ... Common complications after cardiac surgery include postpericardiotomy syndrome ...
    (Date:8/30/2014)... "My niece developed a nighttime fever, ... moment, her fever might get worse," said an inventor ... aware of how she was doing, I developed this ... continuously monitor a child's temperature. The unit instantly alerts ... that prompt medical care can be given, which is ...
    (Date:8/30/2014)... (PRWEB) August 30, 2014 Bringing forth ... By Search announces the Labor Day discount on ... will surely get the complete services related to internet ... professionals, Content Writers, and others do have a deep ... that reflects in their work and since the inception, ...
    (Date:8/30/2014)... PA (PRWEB) August 30, 2014 "I had ... because of her crutches," said an inventor from Wetumpka, Ala. ... sights and sounds of the shore, I came up with ... sand." , She created a prototype for the patent-pending Deezers ... accessory enables the individual to use crutches, walkers, or canes ...
    (Date:8/30/2014)... Bethesda, MD (PRWEB) August 30, 2014 In ... and increasingly difficult to get. Snoring and sleep apnea (a ... stops) robs people and their bed partners of the rest ... to 45% of the population snores and 20 million people ... only 10% have been diagnosed and treated; and of those ...
    Breaking Medicine News(10 mins):Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
    ... difficult for doctors to tell whether a patient with ... inflammation, which can be treated with medicine. A new ... a U-M-led study. Ultrasound elasticity imaging, or UEI, ... inflammation and fibrosis, allowing patients to receive more appropriate ...
    ... State University of New York has received two grants ... of Health (NIH) to support neuroscience and pediatric pharmacology ... collaborative research network of SUNY,s four academic health centers ... both grants will be headquartered at SUNY Downstate Medical ...
    ... who experience new onset breast tenderness after starting combination ... cancer compared to women who don,t experience breast tenderness, ... Center has shown. One reason for this may be ... new onset tenderness was much more pronounced after initiation ...
    ... more effective than the current standard treatment. This is ... treatments, described by Thilo Schwandner and colleagues in the ... Dtsch Arztebl Int 2011; 108[39]: 653-60). In ... The problem is often caused by weakness of the ...
    ... 1982, alone in a laboratory, chemist Dan Shechtman looked ... He had discovered quasicrystals. But his groundbreaking findings ... years. On October 5, 2011, Shechtman received ... to stand by his research? What drove the men ...
    ... News) -- Teen drivers are 50 percent more likely to crash ... are after driving for a full year, according to a study ... drivers are nearly twice as likely to crash in the first ... the study found. However, parents can help teens prevent accidents ...
    Cached Medicine News:Health News:Imaging technology might help doctors determine best treatment for Crohn's disease patients 2Health News:SUNY receives $4.3 million for research in neuroscience, pediatric pharmacology and vision 2Health News:SUNY receives $4.3 million for research in neuroscience, pediatric pharmacology and vision 3Health News:Breast tenderness in women getting combo hormone therapy associated with increase in breast density 2Health News:Breast tenderness in women getting combo hormone therapy associated with increase in breast density 3Health News:How and why did 2011 Nobel winner Dan Shechtman persist despite rejection? 2Health News:Teen Crash Risk High in First Month of Driving, Study Finds 2